Approved for BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older.. Brensocatib is a competitive, reversible inhibitor of dipeptidyl peptidase 1 (DPP1). Side effects, costs, interactions, manufacturer, and generic alternatives sourced from FDA labels, openFDA FAERS, and CMS NADAC pricing.
Loading full data from Know Your Drugs Institute…